Last updated on February 2018

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function


Brief description of study

The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate) relative to matched, healthy controls.

Clinical Study Identifier: NCT02521376

Contact Investigators or Research Sites near you

Start Over

Gilead Study Team

Omega Research Consultants, LLC
Orlando, FL United States
  Connect »